Your business opportunities

Your business opportunities


Medicon Valley is the place to develop your business. The region has a long tradition within biotech and constitutes a fully integrated biotech cluster.

In Medicon Valley there are more than 100 biotech companies with own R&D, major R&D based pharmaceutical companies, more than 200 medtech companies, more than 50 relevant service providers, CRO´s and CMO´s and a dozen experienced life science VC´s - all varying in size and specialization.


> TAKE A CLOSER LOOK



ALK proposes to acquire the largest allergy vaccine company in the Netherlands

> PRINT THIS PAGE
   SHARE
Apr. 26, 2010

ALK and Dutch-based Fornix BioSciences (”Fornix”) have today entered into an agreement to the effect that ALK proposes to acquire the Dutch activities of Fornix’Allergy Division, Artu Biologicals (“Artu”), for a cash consideration of EUR 19.6 million (DKK 146 million) on a debt and cash free basis. The Supervisory Board and the
Board of Management of Fornix have approved and recommend the transaction to the company’s shareholders.

The acquisition is subject to final approval by Fornix’s shareholders. The transaction is expected to become effective on July 1, 2010, after which Artu and ALK’s Dutch subsidiary will be fully integrated.

The proposal to acquire Artu is part of ALK’s strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine industry caused by increased regulatory requirements to products.

The proposed acquisition will strengthen ALK’s market position in the Netherlands and give it a stronger platform for continued growth in its sales of GRAZAX® and other products. Moreover, ALK will use its new market position to distribute coming tabletbased vaccines. Artu’s leading position in the Dutch market is based on close collaboration with allergy doctors within diagnostics and treatment.
The purchase price reflects general market conditions in the Netherlands, where the authorities have implemented tightened reimbursement rules for allergy vaccines. ALK expects that Fornix’ sales of its provisionally registered products can be maintained for the time being. Upon final approval of the transaction, the acquisition will be funded through ALK’s existing cash and cash equivalents.

It is expected that the acquisition will increase ALK’s sales and earnings. ALK will provide specific details regarding the anticipated effect on sales and earnings when the transaction has been completed.


For further information, please contact:

ALK-Abelló A/S
Jens Bager
President and CEO
Telephone +45 4574 7576

Per Plotnikof
Investor Relations
Telephone +45 4574 7527
Mobile phone +45 2261 2525

Or visit: www.alk-abello.com